Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Urinary System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Urinary System Neoplasm

Cancer Family

Urinary System Neoplasm

CI-CAN-00000379Explore in graph →

Non-malignant964 active trials28 approved drugs109 evidence items

NCIt: C3431

Overview
Statistics
Survival
Genomics49
Variants & evidence109
Drugs26
Trials4238
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (244)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 244 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.
· Hum Mutat · 1999 · PMID 10408776 · validated civic_curation pubmed
Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
· Cancer Res · 1994 · PMID 8187067 · validated civic_curation pubmed
Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.
· BMC Cancer · 2005 · PMID 15932632 · validated civic_curation pubmed
VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium.
· Oncogene · 2001 · PMID 11536052 · validated civic_curation pubmed
Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers.
· Int J Cancer · 1995 · PMID 7591282 · validated civic_curation pubmed
Mutations of the VHL tumour suppressor gene in renal carcinoma.
· Nat Genet · 1994 · PMID 7915601 · validated civic_curation pubmed
[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
· Hinyokika Kiyo · 2013 · PMID 23995526 · validated civic_curation

Showing 201–225 of 244 publications

← Previous
1
…
8
9
10
Next →

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.

· Eur J Hum Genet · 2002 · PMID 12461689 · validated civic_curation pubmed

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

· Carcinogenesis · 2006 · PMID 16338952 · validated civic_curation pubmed

Identification of targetable FGFR gene fusions in diverse cancers.

· Cancer Discov · 2013 · PMID 23558953 · validated civic_curation pubmed

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

· Br J Cancer · 2011 · PMID 21119661 · validated civic_curation pubmed

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

· Nat Med · 2006 · PMID 16341243 · validated civic_curation pubmed

PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.

· Anticancer Res · 2013 · PMID 23898052 · validated civic_curation pubmed

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

· Oncogene · 2007 · PMID 17384684 · validated civic_curation pubmed

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

· Oncogene · 2009 · PMID 19749790 · validated civic_curation pubmed

Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method.

· Cancer · 2012 · PMID 22252991 · validated civic_curation pubmed

Circadian regulation of mTOR by the ubiquitin pathway in renal cell carcinoma.

· Cancer Res · 2014 · PMID 24253377 · validated civic_curation pubmed

Damrauer et al. Nat Commun. 2022

· 2022 · PMID 36333289 · validated cbioportal_study pubmed

Guo et al. Nat Genet 2013

· 2013 · PMID 24121792 · validated cbioportal_study pubmed

Faltas and Prandi, Nature Genetics 2016

· 2016 · PMID 27749842 · validated cbioportal_study pubmed

Van Allen et al. Cancer Discov 2014

· 2014 · PMID 25096233 · validated cbioportal_study pubmed

Iyer, Gopa et al. JCO precision oncology 2024

· 2024 · PMID 39499893 · validated cbioportal_study pubmed

Brendan J et al. Eur Urol Open Sci 2025

· 2025 · PMID 40256659 · validated cbioportal_study pubmed

Pietzak et al. Eur Urol 2019

· 2019 · PMID 30290956 · validated cbioportal_study pubmed

Iyer et al. J Clin Oncol 2013

· 2013 · PMID 23897969 · validated cbioportal_study pubmed